-
Deutsche Bank Maintains ILMN's Buy Rating
Tuesday, March 15, 2011 - 8:36am | 108Deutsche Bank reports that Illumina (NASDAQ: ILMN) will remain at a Buy Rating after its announcement to raise $800 million of convertible Senior Notes by 2016. The report stated, "We believe that today's announcement is a positive for the stock, given that some investors had viewed the increased...
-
Top 4 Small-Cap Stocks In The Medical Laboratories & Research Industry With The Highest Revenue (PRXL, ICLR, AIQ, BRLI)
Tuesday, March 15, 2011 - 3:03am | 144Below are the top small-cap medical laboratories & research stocks on the NYSE and the NASDAQ in terms of revenue. The trailing-twelve-month revenue at PAREXEL International Corporation (NASDAQ: PRXL) is $1.40 billion. PRXL's ROE for the same period is 12.58%. The trailing-twelve-month...
-
Enzo Biochem Reports Q2 EPS of $(0.15) vs. $(0.10)
Monday, March 14, 2011 - 4:33pm | 140Enzo Biochem, Inc. (NYSE: ENZ) today reported improved results for the second fiscal quarter ended January 31, 2011. Total revenue for the second quarter of fiscal 2011 increased 2% to $23.7 million, from $23.2 million a year ago, primarily as a result of higher revenue at Enzo Clinical Labs,...
-
Illumina to Offer $800 Million Convertible Senior Notes; Expects to Use up to $425M to Repurchase Shares
Monday, March 14, 2011 - 4:10pm | 138Illumina, Inc. (NASDAQ: ILMN) today announced its intention to offer, subject to market and other conditions, approximately $800 million principal amount of Convertible Senior Notes due 2016 through offerings to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933,...
-
ILMN $800M In Convertible Senior Notes (ILMN)
Monday, March 14, 2011 - 4:07pm | 20Illumina (NASDAQ: ILMN) to offer $800M in convertible senior notes.
-
Health Insurers Triple S&P 500 Returns
Thursday, March 10, 2011 - 1:21pm | 664By Josh Lipton In the past month, while violent unrest in the Middle East and North Africa has dramatically dominated the investment headlines, strategists note that one sector has quietly emerged under the radar: Health Care. In fact, month-to-date, the S&P 500 is down .41%. However, there...
-
Oppenheimer Reiterates WuXi PharmaTech Outperform (WX)
Thursday, March 10, 2011 - 9:32am | 139Oppenheimer reiterated its WuXi PharmaTech (NYSE: WX) Outperform rating in a research report published today. Oppenheimer has previously given WuXi PharmaTech a $20 price target. In the report, Oppenheimer states, "WX continues to impress the Street with stellar performance and strong guidance....
-
J.P. Morgan Reiterates WuXi PharmaTech Overweight, $23 PT (WX)
Thursday, March 10, 2011 - 9:03am | 153J.P. Morgan reiterated its WuXi PharmaTech (NYSE: WX) Overweight rating and $23 price target in a research report published today. In the report, J.P. Morgan states, "Following the January (1/10) pre-announcement of 4Q revenues and operating margins above guidance, 4Q results provided few...
-
Puts Purchased on Thermo Fisher Scientific (TMO)
Wednesday, March 9, 2011 - 12:50pm | 140Shares of Thermo Fisher Scientific (NYSE: TMO) are lower on the session by 1.60%, currently trading at $55.98. The stock has been moving largely higher over the past six months and is currently trading above the 50-day and 200-day moving averages. Options traders are buying puts on the name today...
-
Options Brief: Bruker Corporation (BRKR)
Wednesday, March 9, 2011 - 11:35am | 94Shares of Bruker Corporation (NASDAQ: BRKR) are higher on the session by 0.43%, trading at $19.82. Overall call volume is now running at 80.40x the daily average, with 0% of all calls traded being purchases on the offer. 2,010 contracts have traded on the session so far. Bruker Corporation is a...
-
Oppenheimer Maintains Outperform on WuXi PharmaTech (WX)
Wednesday, March 9, 2011 - 10:21am | 115Oppenheimer is out with its report today on WuXi Pharmatech (NYSE: WX), maintaining Outperform. In a note to clients, Oppenheimer writes, "We believe WX is well positioned to benefit from China's growing CRO (contract research organization) market, driven by the continued global R&D...
-
Piper Jaffray Maintains Rating And Price Target On Sequenom
Wednesday, March 9, 2011 - 8:54am | 82In a report published by Piper Jaffray, Sequenom (NASDAQ: SQNM) reported revenue and LPS above its, and Street, consensus expectations. Piper Jaffray said that Sequenom generally remains on-track for the T21 assay LDT launch by the end of the year (or early 2012). “We are encouraged with the...
-
Auriga Says Sequenom Is All Quiet Ahead Of Data Storm
Wednesday, March 9, 2011 - 8:21am | 174In a report published by Auriga, Sequenom (NASDAQ: SQNM) is all quiet ahead of the data storm. Auriga said that Sequenom reported essentially in-line 4Q10 results and provided an update on key next steps in its AMD (Age-Related Macular Degeneration) and T21 clinical diagnostic programs. “SQNM's T-...
-
Sequenom Reports EPS of $(0.27) vs. $(0.21)
Tuesday, March 8, 2011 - 5:36pm | 119Sequenom, Inc. (Nasdaq: SQNM) today reported its financial results for the fourth quarter and the year ended December 31, 2010. Total revenue for the fourth quarter of 2010 grew 28% to $13.8 million, compared with $10.8 million for the fourth quarter of 2009. Net loss for the fourth quarter of...
-
WuXi PharmaTech Reports EPS of $0.28 vs. $0.21
Tuesday, March 8, 2011 - 5:31pm | 49WuXi PharmaTech (Cayman) Inc. (NYSE: WX) today announced its financial results for fourth-quarter and full-year 2010. Net revenues grew 20% year over year to $88.6 million Non-GAAP diluted earnings per ADS grew 29% year over year to 28 cents